Traditional oral weight loss medications mainly included drugs that suppressed appetite or inhibited fat absorption, but the market is now being defined by new oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other metabolic disease medications
Any time a needle is inserted through the skin, there is a possibility of infection
It is associated with increased BDNF activity, improved cerebral blood flow, and enhanced cognitive resilience
Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)
Read the full FDA Warning Letter here: #FDA #WarningLetter #PharmaCompliance #GLP1 #Semaglutide #Tirzepatide #DrugSafety #QualityMatters #Zenovel# To view or add a comment, sign in So many interesting insights from the Symposium, including on implementation of the new EU variation guidelines, the future of ePI and biosimilars, and the impact of the EU's HTA Regulation and General Pharmaceutical Legislation